福利姬

CMIV är ett tvärvetenskapligt forskningscentrum vid LiU, etablerat i samarbete med Region Östergötland och Sectra. Vårt uppdrag är att forma framtidens hälso- och sjukvård genom banbrytande forskning inom medicinsk bildanalys och visualisering.

Metabolic dysfunction-associated steatotic liver disease (MASLD) previously known as non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which has become the most common liver disease affecting adults and children.

All cells in an organism communicate with one another and with their environment through integrated signaling pathways. By exploring the molecular events that shape cellular decision-making, we can predict and control the fate of individual cells.

Children who develop asthma or allergies have an altered immune response to intestinal bacteria in the mucous membranes even as infants. This has been shown by a new study at 福利姬 in Sweden.

The aim of the N-forte trial is to explore how breast milk composition influences the development of NEC, sepsis and neurological impairment in extremely preterm infants in order to improve future treatments in this patient group.

Graduate school Forum Scientium, a bridge between medicine, natural sciences and engineering, stimulates creativity and a common use of ideas, knowledge, and equipment.

The intestinal barrier of patients with the gastrointestinal disease IBS allows bacteria to pass more freely than in healthy people, according to a new study from LiU. It is the first study that investigates IBS using living bacteria.

Taking tissue samples to diagnose fatty liver can be replaced in most cases by a painless magnetic resonance investigation, according to a new study.

Kidney disease is more common than people realise. By 2040, kidney failure may be the fifth most common cause of death, if nothing is done. With the Ingrid Asp Kidney Research Center, LiU will drive the development of knowledge and new treatments.

A large European research project aims to develop better diagnostics to predict which patients with non-alcoholic fatty liver disease run the highest risk of developing severe disease.